Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCNN1A | P37088 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028705 | 0.99 | SCNN1A (0.65) | SCNN1A | |
| SCHEMBL14180722 | 0.96 | SCNN1A (0.64) | SCNN1A | |
| SCHEMBL9913772 | 0.92 | SCNN1A (0.64) | SCNN1A | |
| SCHEMBL14456662 | 0.91 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL9913777 | 0.91 | SCNN1A (0.57) | SCNN1A | |
| SCHEMBL9913768 | 0.91 | SCNN1A (0.65) | SCNN1A | |
| SCHEMBL707971 | 0.90 | SCNN1A (0.55) | SCNN1A | |
| Hydrochloric Acid SCHEMBL19348118 | 0.90 | SCNN1A (0.56) | SCNN1A | |
| SCHEMBL16808735 | 0.90 | SCNN1A (0.54) | SCNN1A | |
| SCHEMBL2054438 | 0.90 | SCNN1A (0.54) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314105-B2 | Methods of reducing risk of infection from pathogens | PARION SCIENCES, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314105-B2 | Methods of reducing risk of infection from pathogens | PARION SCIENCES, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120165342-A1 | Methods of Reducing Risk of Infection from Pathogens | PARION SCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165342-A1 | Methods of Reducing Risk of Infection from Pathogens | PARION SCIENCES, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110144338-A1 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144338-A1 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | PARION SCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7745442-B2 | Methods of reducing risk of infection from pathogens | PARION SCIENCES, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745442-B2 | Methods of reducing risk of infection from pathogens | PARION SCIENCES, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7368450-B2 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368450-B2 | Antihistamines; bronchodilators; antiinflammatory agents; inflammatory bowel disorders | PARION SCIENCES, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1485359-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247636-B2 | Phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241766-B2 | Methods of using phenolic guanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192959-B2 | Antihistamines; antiinflammatory agents; bronchodilator agents; inflammatory bowel disorders; psoriasis | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192958-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165342-A1 | Methods of Reducing Risk of Infection from Pathogens | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
| US-20110144338-A1 | METHODS OF REDUCING RISK OF INFECTION FROM PATHOGENS | KCNN3, KCNN1, KCNN2 | SCNN1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.